SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021240
Filing Date
2023-05-11
Accepted
2023-05-11 16:11:44
Documents
70
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-20230331.htm   iXBRL 10-Q 2832946
2 EX-31.1 trvi-ex31_1.htm EX-31.1 20632
3 EX-31.2 trvi-ex31_2.htm EX-31.2 20606
4 EX-32.1 trvi-ex32_1.htm EX-32.1 14219
5 EX-32.2 trvi-ex32_2.htm EX-32.2 14179
  Complete submission text file 0000950170-23-021240.txt   10655924

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trvi-20230331_pre.xml EX-101.PRE 370578
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trvi-20230331_lab.xml EX-101.LAB 514729
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trvi-20230331.xsd EX-101.SCH 60109
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT trvi-20230331_cal.xml EX-101.CAL 64028
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT trvi-20230331_def.xml EX-101.DEF 194240
64 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20230331_htm.xml XML 2200581
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 23911132
SIC: 2834 Pharmaceutical Preparations